The uniqueness of flow in probing the aggregation behavior of clinically relevant antibodies

Abstract

The development of therapeutic monoclonal antibodies (mAbs) can be hindered by their tendency to aggregate throughout their lifetime, which can illicit immunogenic responses and render mAb manufacturing unfeasible. Consequently, there is a need to identify mAbs with desirable thermodynamic stability, solubility, and lack of self-association. These behaviors are assessed using an array of in silico and in vitro assays, as no single assay can predict aggregation and developability. We have developed an extensional and shear flow device (EFD), which subjects proteins to defined hydrodynamic forces which mimic those experienced in bioprocessing. Here, we utilize the EFD to explore the aggregation propensity of 33 IgG1 mAbs, whose variable domains are derived from clinical antibodies. Using submilligram quantities of material per replicate, wide-ranging EFD-induced aggregation (9-81% protein in pellet) was observed for these mAbs, highlighting the EFD as a sensitive method to assess aggregation propensity. By comparing the EFD-induced aggregation data to those obtained previously from 12 other biophysical assays, we show that the EFD provides distinct information compared with current measures of adverse biophysical behavior. Assessing a candidate's liability to hydrodynamic force thus adds novel insight into the rational selection of developable mAbs that complements other assays. K E Y W O R D S aggregation, developability, extensional flow, monoclonal antibody, shear flowThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches

“…These investigations have provided valuable data on neonatal Fc receptor (FcRn) column or heparin column retention times, 8 polyreactivity to cofactors heme or folate, 7 nitroarenes, 9 induced polyreactivity on exposure to oxidative agents, 6 polyreactivity to chaperone proteins 10 or protein mixtures, 11 and induced aggregation on flow stress. 12 …”

Combining Unfolding Reversibility Studies and Molecular Dynamics Simulations to Select Aggregation-Resistant Antibodies

“…However, not all antibodies with the desired antigen-binding properties will possess features that make them suitable to become drugs. The drug-like properties of an antibody are related to various characteristics like low-aggregation propensity, high thermal stability, high specificity, and low viscosity at high protein concentrations. − Identifying the candidates with drug-like properties at a very early stage is a part of a developability assessment strategy that aims to mitigate the risk that an antibody fails to pass checkpoints en route to becoming a marketed product. The informed early selection of the most promising candidates can save resources and help avoid project delays.…”